$JNJ

Broadhurst Vanessa sold $5.8M of JNJ

Broadhurst Vanessa (EVP, Global Corp Affairs) sold 23,054 shares of JOHNSON & JOHNSON (JNJ) at $251.27 ($5.79M total) on 2026-07-20.

Original reporting
SEC EDGAR · Broadhurst Vanessa
Published Jul 21, 2026, 9:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
high confidence
Mentioned
$JNJ
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new company-specific fundamentals or forward-looking guidance.

02

Market read

Traders may monitor for patterns in insider activity, but this single sale is unlikely to drive a material repricing without additional catalysts.

03

What to watch

The text notes no 10b5-1 plan and shows post-transaction holdings, but it still lacks context on compensation, tax needs, or whether sales were part of a broader pattern.

Relevance 6/10Novelty 2/10Timing: Filed 2026-07-21, covering a sale executed 2026-07-20.

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralHigh confidence
Context

Johnson & Johnson disclosed an EVP global corporate affairs open-market sale of 23,054 shares at $251.2660 on 2026-07-20 via Form 4.

Expected impact

Likely minimal price impact; any effect is short-lived unless accompanied by other disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with no guidance, earnings, legal, or operational catalyst included in the text.

Market effects

No sector read-through; this is company-specific insider trading without new regulatory, product, or litigation facts.

None indicated.

None indicated.

Counterpoint

Insider sales are often pre-planned for diversification or liquidity, so the signal may be noise rather than bearish information.

Key entities

  • Johnson & Johnson

    Subject of the Form 4 insider transaction disclosure.

  • Broadhurst Vanessa

    EVP, Global Corp Affairs who sold shares in an open-market transaction.

Related articles

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

$JNJMedAI 8/10

Mary Alexander Applauds Historic Johnson & Johnson Talc Settlement, Calling It a Long-Overdue Measure of Justice for Thousands of Women

Attorney Mary Alexander said a proposed minimum $5.5 billion talc settlement involving Johnson & Johnson could compensate tens of thousands of plaintiffs alleging ovarian cancer from J&J talc-based products. Alexander’s firm represents affected women and families, and said J&J denies liability. The settlement follows years of litigation and appeals, with J&J previously seeking bankruptcy resolution.